BRPI1007230B1 - polipeptídeo apresentando a antigenicidade de stx2, seus usos, composição compreendendo o mesmo e célula hospedeira - Google Patents

polipeptídeo apresentando a antigenicidade de stx2, seus usos, composição compreendendo o mesmo e célula hospedeira Download PDF

Info

Publication number
BRPI1007230B1
BRPI1007230B1 BRPI1007230-6A BRPI1007230A BRPI1007230B1 BR PI1007230 B1 BRPI1007230 B1 BR PI1007230B1 BR PI1007230 A BRPI1007230 A BR PI1007230A BR PI1007230 B1 BRPI1007230 B1 BR PI1007230B1
Authority
BR
Brazil
Prior art keywords
stx2
seq
antibody
stx1
antibodies
Prior art date
Application number
BRPI1007230-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Alison O'Brien
Angela Melton-Celsa
Michael Smith
James Sinclair
Original Assignee
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. filed Critical The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
Publication of BRPI1007230A2 publication Critical patent/BRPI1007230A2/pt
Publication of BRPI1007230B1 publication Critical patent/BRPI1007230B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
BRPI1007230-6A 2009-01-23 2010-01-21 polipeptídeo apresentando a antigenicidade de stx2, seus usos, composição compreendendo o mesmo e célula hospedeira BRPI1007230B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14689209P 2009-01-23 2009-01-23
US61/146,892 2009-01-23
US21008209P 2009-03-13 2009-03-13
US61/210,082 2009-03-13
PCT/US2010/021610 WO2010085539A1 (en) 2009-01-23 2010-01-21 Methods and compositions based on shiga toxin type 2 protein

Publications (2)

Publication Number Publication Date
BRPI1007230A2 BRPI1007230A2 (pt) 2016-02-16
BRPI1007230B1 true BRPI1007230B1 (pt) 2019-11-12

Family

ID=42356196

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007230-6A BRPI1007230B1 (pt) 2009-01-23 2010-01-21 polipeptídeo apresentando a antigenicidade de stx2, seus usos, composição compreendendo o mesmo e célula hospedeira

Country Status (16)

Country Link
US (2) US8969529B2 (https=)
EP (1) EP2381954B8 (https=)
JP (1) JP5773886B2 (https=)
KR (1) KR101832499B1 (https=)
CN (1) CN102292098A (https=)
AR (1) AR075047A1 (https=)
AU (1) AU2010206800B2 (https=)
BR (1) BRPI1007230B1 (https=)
CA (1) CA2748873C (https=)
CL (1) CL2011001769A1 (https=)
ES (1) ES2614803T3 (https=)
MX (1) MX2011007866A (https=)
NZ (1) NZ593926A (https=)
PE (1) PE20120425A1 (https=)
RU (1) RU2011126896A (https=)
WO (1) WO2010085539A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229045A1 (en) * 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
US8293245B2 (en) 2006-04-20 2012-10-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 1 protein
WO2010085539A1 (en) 2009-01-23 2010-07-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
US9310368B1 (en) * 2012-09-28 2016-04-12 The United States Of America, As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies for detection of Shiga toxin 2 (STX2)
US9513287B1 (en) * 2012-09-28 2016-12-06 The United States Of America, As Represented By The Secretary Of Agriculture High affinity monoclonal antibodies for detection of shiga toxin 2
EP3666795A1 (en) * 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
CN103343164B (zh) * 2013-06-17 2016-05-18 武汉轻工大学 产志贺毒素大肠杆菌多重pcr检测方法、试剂盒及应用
RU2573924C2 (ru) * 2013-07-11 2016-01-27 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) НЕТОКСИЧНЫЙ РЕКОМБИНАНТНЫЙ ШИГА ТОКСИН 2-ГО ТИПА (Stx2)
CN112851769A (zh) * 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
CN104558167B (zh) * 2014-12-26 2017-12-26 江苏省疾病预防控制中心 检测i型志贺毒素双抗夹心法酶联免疫试剂盒及其应用
EP3253799B1 (en) 2015-02-05 2020-12-02 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
CN115856296B (zh) * 2022-12-16 2023-07-25 华北理工大学 抗志贺氏菌的单克隆抗体及其检测中的应用
CN120647752B (zh) * 2025-08-19 2025-10-28 中国人民解放军军事科学院军事医学研究院 一种抗ⅱ型志贺毒素的单克隆抗体及其相关产品和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5164298A (en) 1988-06-24 1992-11-17 Hsc Research Development Corporation Verocytotoxin receptor assay
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5552144A (en) * 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants
US5747272A (en) 1994-02-14 1998-05-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine Detection of shiga-like toxins of enterohemoragic Escherichia coli
US5968894A (en) 1994-02-22 1999-10-19 Lingwood; Clifford A. Verotoxin pharmaceutical compositions and medical treatments therewith
JP2001500730A (ja) 1996-09-10 2001-01-23 ヘンリー エム ジャクソン ファンデーション フォージ アドバンスメント オブ ミリタリー メディシン ヒスチジン―タグ付き志賀毒素およびトキソイド、該毒素およびトキソイドとの融合タンパク質ならびにそれらの精製及び調製方法
WO1998020903A1 (en) 1996-11-15 1998-05-22 Trustees Of Tufts College Humanized neutralizing antibodies against hemolytic uremic syndrome
US7910096B2 (en) 1996-11-15 2011-03-22 Trustees Of Tufts College Human neutralizing antibodies against hemolytic uremic syndrome
US20020160005A1 (en) * 1996-11-15 2002-10-31 Trustees Of Tufts College Human neutralizing antibodies against hemolytic urmec syndrome
US20030170248A1 (en) * 1997-12-23 2003-09-11 Jeffrey R. Stinson Humanized monoclonal antibodies that protect against shiga toxin induced disease
ES2270598T3 (es) 1998-05-20 2007-04-01 Teijin Limited Anticuerpos humanizados que reconocen la verotoxina ii y linea celular que produce los mismos.
US7807184B2 (en) * 2003-07-21 2010-10-05 Interuet International B.V. Hybrid Shiga-like toxin
EP1694845B8 (en) 2003-11-28 2017-12-20 National Research Council of Canada Anticarcinoma antibodies and uses thereof
US20050226883A1 (en) 2004-02-06 2005-10-13 Paul Averback Humanized antibody
CA2458084A1 (en) 2004-03-12 2005-09-12 Dalton Chemical Laboratories Inc. Novel process for octreotide synthesis
WO2006091677A1 (en) 2005-02-22 2006-08-31 Jean Gariepy Yeast strains expressing ribosome-inactivating protein domain and method of using same
ES2532985T3 (es) * 2006-02-16 2015-04-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Proteínas quiméricas de toxoide de Shiga
US8293245B2 (en) 2006-04-20 2012-10-23 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on Shiga toxin type 1 protein
US20090258010A1 (en) 2006-05-31 2009-10-15 Thallion Pharmaceuticals, Inc. Methods, compositions, and kits for treating shiga toxin associated conditions
EP2545936A3 (en) 2006-05-31 2013-02-20 Thallion Pharmaceuticals Inc. Methods, compositions, and kits for treating Shiga toxin associated conditions
EP2097529A4 (en) * 2006-12-29 2010-03-24 Osprey Pharmaceuticals Usa Inc METHOD FOR SELECTION AND PRODUCTION OF MODIFIED TOXINS, MODIFIED TOXINE CONJUGATES AND USES THEREOF
US20100298238A1 (en) 2007-10-08 2010-11-25 Rutgers, The State University Nontoxic shiga-like toxin mutant compositions and methods
CN101314616B (zh) 2008-05-30 2011-05-11 中国人民解放军第三军医大学 肠出血性大肠杆菌o157:h7志贺毒素ⅱb表位肽及其应用
US20110165680A1 (en) * 2008-09-12 2011-07-07 Scarab Genomics, Llc Clean genome bactofection
WO2010085539A1 (en) 2009-01-23 2010-07-29 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein

Also Published As

Publication number Publication date
NZ593926A (en) 2013-03-28
WO2010085539A1 (en) 2010-07-29
EP2381954B8 (en) 2017-01-25
EP2381954A4 (en) 2012-08-01
EP2381954B1 (en) 2016-11-02
US8969529B2 (en) 2015-03-03
CA2748873C (en) 2017-09-12
AR075047A1 (es) 2011-03-02
AU2010206800B2 (en) 2016-06-30
BRPI1007230A2 (pt) 2016-02-16
CN102292098A (zh) 2011-12-21
KR20110119725A (ko) 2011-11-02
KR101832499B1 (ko) 2018-02-26
PE20120425A1 (es) 2012-05-03
MX2011007866A (es) 2011-10-06
JP5773886B2 (ja) 2015-09-02
US20110318357A1 (en) 2011-12-29
US9801931B2 (en) 2017-10-31
AU2010206800A1 (en) 2011-07-28
JP2012515551A (ja) 2012-07-12
ES2614803T3 (es) 2017-06-02
RU2011126896A (ru) 2013-02-27
EP2381954A1 (en) 2011-11-02
US20160243210A1 (en) 2016-08-25
CA2748873A1 (en) 2010-07-29
CL2011001769A1 (es) 2012-08-31

Similar Documents

Publication Publication Date Title
US9801931B2 (en) Methods and compositions based on Shiga toxin type 2 protein
AU2007240614B2 (en) Methods and compositions based on Shiga toxin type 1 protein
EP1280828B1 (en) Anthrax-specific antigen, vaccines comprising said antigen, anthrax-specific antibodies, and their uses
PT2857418T (pt) Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
Rosenqvist et al. Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis
JP4355786B2 (ja) シュードモナスｖ抗原を用いる免疫化のための方法および組成物
US5955293A (en) Assays for shiga toxin and shiga-like toxins
BRPI1014505B1 (pt) Proteína de fusão de múltiplos epítopos, método para produzir uma composição, polinucleotídeo, vetor recombinante, célula hospedeira, método para produzir umaproteína de fusão de múltiplos epítopos, kit de teste imunodiagnóstico, composição, e, uso de uma proteína de fusão de múltiplos epítopos
RU2555530C2 (ru) СПОСОБ ИДЕНТИФИКАЦИИ ПОЛИПЕПТИДОВ И БЕЛКОВ H.parasuis
ES2358804T3 (es) Polipéptidos de campylobacter jejuni ubicados en superficie.
US9475864B2 (en) Methods, compositions and vaccines relating to Neisseria meningitidis antibodies
US7718779B2 (en) Prophylactic and therapeutic monoclonal antibodies
US20040258695A1 (en) Transferrin binding peptides and uses thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/01/2010, OBSERVADAS AS CONDICOES LEGAIS. (CO) 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/01/2010, OBSERVADAS AS CONDICOES LEGAIS

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2863 DE 18-11-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.